A detailed history of Group One Trading, L.P. transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 11,695 shares of CAPR stock, worth $59,878. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,695
Holding current value
$59,878
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.63 - $7.09 $54,147 - $82,917
11,695 New
11,695 $55,000
Q4 2023

Feb 14, 2024

SELL
$2.71 - $5.08 $92,037 - $172,526
-33,962 Reduced 94.42%
2,006 $9,000
Q3 2023

Nov 09, 2023

BUY
$3.42 - $7.85 $31,806 - $73,005
9,300 Added 34.87%
35,968 $123,000
Q2 2023

Aug 09, 2023

SELL
$3.76 - $5.05 $2,530 - $3,398
-673 Reduced 2.46%
26,668 $127,000
Q1 2023

May 12, 2023

BUY
$3.78 - $5.03 $16,235 - $21,603
4,295 Added 18.64%
27,341 $115,000
Q4 2022

Feb 09, 2023

SELL
$3.36 - $6.55 $76,896 - $149,903
-22,886 Reduced 49.83%
23,046 $88,000
Q3 2022

Nov 09, 2022

SELL
$3.61 - $6.08 $28,324 - $47,703
-7,846 Reduced 14.59%
45,932 $276,000
Q2 2022

Aug 11, 2022

BUY
$2.89 - $4.51 $60,464 - $94,358
20,922 Added 63.68%
53,778 $188,000
Q1 2022

May 12, 2022

BUY
$2.83 - $5.68 $29,106 - $58,418
10,285 Added 45.57%
32,856 $113,000
Q4 2021

Feb 11, 2022

BUY
$2.89 - $4.16 $9,791 - $14,094
3,388 Added 17.66%
22,571 $66,000
Q3 2021

Nov 12, 2021

SELL
$3.8 - $5.23 $209,638 - $288,528
-55,168 Reduced 74.2%
19,183 $77,000
Q2 2021

Aug 10, 2021

BUY
$3.16 - $5.72 $105,107 - $190,258
33,262 Added 80.95%
74,351 $381,000
Q1 2021

May 12, 2021

BUY
$3.63 - $7.93 $149,153 - $325,835
41,089 New
41,089 $192,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $125M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.